Trust Company’s CONMED CNMD Stock Holding History

Trust Company’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-423	Closed	-$63K	–	331
2022 Q1	$63K	Buy	+423	New	+$59.1K	0.01%	185

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Trust Company's CNMD Position: Q2 2022 in Review

Trust Company sold out of CONMED (CNMD) in Q2 2022, closing a stake of 423 shares — an estimated $63K sold.

Trust Company first reported a position in CNMD in Q1 2022 and held it in 1 quarter. The position peaked at $63K in Q1 2022. 280 funds tracked by Wall St. Rank hold CNMD as of Q2 2022.

Trust Company reported no remaining CONMED position as of Q2 2022 after selling out during the quarter.
Trust Company sold 423 CONMED shares in Q2 2022, an estimated $63K.
Trust Company first reported a position in CONMED in Q1 2022 and held it in 1 quarter.
Trust Company's CONMED position peaked at $63K in Q1 2022.
280 funds tracked by Wall St. Rank held CONMED as of Q2 2022.

Based on Trust Company's 13F filing for Q2 2022, filed 6 Jul 2022.